SecBot SecBot
PRESS-RELEASE ·Filed Nov 6, 2026

TARA

Protara Therapeutics
NEUTRAL
Impact 4/10
Horizonweeks Processed10d 18h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Watch for enrollment completion of the BCG-Unresponsive NMIBC cohort by year-end and interim THRIVE-3 Phase 2b results, both catalysts for TARA-002 and IV Choline Chloride programs. The in-sourcing of manufacturing adds operational control but increases near-term cash burn.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$2.30
T+0 close · Nov 6, 2026 · via day close
Latest settled
+10.00%
T+5 · $2.53
Vs SPY
+7.41%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $2.30entry
  2. T+1 · 8d ago +9.13%α +6.76% · $2.51
  3. T+5 · 4d ago +10.00%α +7.41% · $2.53
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics reported a Q3 2026 net loss of $21.7M ($0.35 per share), wider than the $13.3M loss a year ago, as R&D spending rose to $16.8M. The company provided clinical updates: expects to complete enrollment of the BCG-Unresponsive NMIBC cohort by year-end 2026 and the STARBORN-1 LM trial in early Q1 2027, with a rolling BLA for TARA-002 in LMs targeted for 2H 2027. Cash of $143M is expected to fund operations into 2028.

Key Financial Metrics

EPS
−$0.35
Revenue
$0.00
est $0.00

Key Facts

  • Q3 2026 net loss $21.7M ($0.35/sh) vs $13.3M ($0.31/sh) in Q3 2025
  • R&D expenses $16.8M, up from $9.6M year-over-year
  • Cash, equivalents and marketable debt securities $143.1M as of Sep 30, 2026
  • Expects to complete enrollment of BCG-Unresponsive NMIBC cohort by year-end 2026
  • STARBORN-1 LM trial enrollment now expected to complete early Q1 2027
  • Rolling BLA submission for TARA-002 in LMs expected in 2H 2027
  • Acquired TARA-002 manufacturing assets from Novex Innovations for $8.75M
  • THRIVE-3 Phase 2b enrollment completed; interim results expected by year-end 2026

Financial Impact

Net loss widened by $8.4M vs prior year; cash burn increased; $143M cash runway into 2028

net lossR&D expensecash position

Risk Factors

  • Clinical trial enrollment delays (STARBORN-1 pushed to early Q1 2027)
  • Rising R&D spend without near-term revenue
  • Regulatory risk for BLA submission and FDA approval of TARA-002

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397475

Track record

13 reports on TARA

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +17.50% at T+60 after the May 26, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
  2. Nov 6, 202610d ago 8-K Neutral 4/10 No price data
  3. Nov 6, 202610d ago Press Release Neutral 4/10 Viewing Entry $2.30 Now $2.38 +3.48% settles Feb 4
  4. Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
  5. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  6. Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
  7. Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
  8. May 26, 202625w ago EFFECT Bearish 5/10 Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
  9. May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
  10. May 13, 202626w ago 8-K Neutral 4/10 No price data
Showing 10 of 13

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026